BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
Phase 1
Completed
- Conditions
- Medical Oncology
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT02457351
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
Phase 1
Completed
- Conditions
- Clinical Trial, Phase I
- Interventions
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT02456129
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4
- Registration Number
- NCT02455297
A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 49
- Registration Number
- NCT02452515
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Completed
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 86
- Registration Number
- NCT02450812
- Locations
- 🇩🇪
Many Locations, Multiple Locations, Germany
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Phase 1
Completed
- Conditions
- NeoplasmsBone Diseases
- Interventions
- Drug: Radium Ra 223 dichloride (Xofigo, BAY88-8223)
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT02442063
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
Phase 1
Terminated
- Conditions
- Medical Oncology
- Interventions
- Drug: BAY1143269 tablet
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT02439346
Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT02434640
Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 882
- Registration Number
- NCT02428985
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan
Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 646
- Registration Number
- NCT02425501
© Copyright 2025. All Rights Reserved by MedPath